buspirone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anxiolytics, buspirone derivatives 437 36505-84-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • buspirone
  • buspin
  • buspirone hydrochloride
  • buspirone HCl
An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
  • Molecular weight: 385.51
  • Formula: C21H31N5O2
  • CLOGP: 2.24
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 0
  • TPSA: 69.64
  • ALOGS: -2.82
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.59 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 3.90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 29, 1986 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 525.87 13.08 476 28818 145197 63314531
Serotonin syndrome 225.30 13.08 149 29145 28533 63431195
Depression 157.69 13.08 306 28988 196186 63263542
Suicidal ideation 146.91 13.08 162 29132 62259 63397469
Anxiety 133.96 13.08 304 28990 217237 63242491
Toxicity to various agents 98.01 13.08 293 29001 246957 63212771
Contraindicated product administered 83.69 13.08 4 29290 217644 63242084
Product dose omission issue 78.43 13.08 262 29032 234051 63225677
Withdrawal syndrome 69.23 13.08 64 29230 19933 63439795
Drug intolerance 67.49 13.08 29 29265 308632 63151096
Synovitis 59.33 13.08 8 29286 186910 63272818
Hand deformity 55.21 13.08 5 29289 159452 63300276
Treatment failure 53.53 13.08 13 29281 199030 63260698
Panic attack 52.56 13.08 58 29236 22273 63437455
Dermatitis atopic 52.02 13.08 40 29254 9684 63450044
Cardio-respiratory arrest 47.49 13.08 93 29201 59866 63399862
Insomnia 46.77 13.08 210 29084 215042 63244686
Systemic lupus erythematosus 45.04 13.08 20 29274 208898 63250830
Migraine 44.22 13.08 126 29168 103220 63356508
General physical health deterioration 43.86 13.08 19 29275 201383 63258345
Disturbance in attention 42.85 13.08 69 29225 38120 63421608
Tremor 42.52 13.08 146 29148 132093 63327635
Suspected suicide 41.82 13.08 30 29264 6538 63453190
Wound 41.36 13.08 12 29282 163251 63296477
Somnolence 40.83 13.08 177 29117 178508 63281220
Joint swelling 39.72 13.08 56 29238 327610 63132118
Infusion related reaction 39.69 13.08 33 29261 245488 63214240
Agitation 39.46 13.08 86 29208 59671 63400057
Drug abuse 38.71 13.08 96 29198 72422 63387306
Overdose 38.71 13.08 129 29165 114949 63344779
Arthropathy 37.41 13.08 32 29262 234760 63224968
Stiff person syndrome 36.17 13.08 11 29283 321 63459407
Drug withdrawal syndrome 35.94 13.08 53 29241 27141 63432587
Febrile neutropenia 35.44 13.08 6 29288 118443 63341285
Anoxia 35.31 13.08 10 29284 226 63459502
Hepatic enzyme increased 32.94 13.08 27 29267 202301 63257427
Swelling 32.44 13.08 48 29246 275330 63184398
Intentional overdose 32.29 13.08 91 29203 74061 63385667
Thrombocytopenia 31.74 13.08 15 29279 151142 63308586
Pre-existing condition improved 31.71 13.08 28 29266 8216 63451512
Feeling abnormal 31.62 13.08 144 29150 148248 63311480
Alopecia 31.52 13.08 68 29226 337468 63122260
Hypothermia 31.49 13.08 35 29259 13546 63446182
COVID-19 31.36 13.08 119 29175 112984 63346744
Neutropenia 30.20 13.08 22 29272 174983 63284745
Emotional disorder 30.20 13.08 34 29260 13345 63446383
Lower respiratory tract infection 29.57 13.08 12 29282 132295 63327433
Total cholesterol/HDL ratio abnormal 29.41 13.08 7 29287 77 63459651
Mental disorder 29.31 13.08 47 29247 25872 63433856
Drug screen false positive 28.99 13.08 12 29282 872 63458856
Psoriasis 28.81 13.08 97 29197 86860 63372868
Surgery 28.79 13.08 56 29238 35856 63423872
Suicide attempt 28.75 13.08 77 29217 60841 63398887
Anger 28.70 13.08 32 29262 12424 63447304
Rheumatoid arthritis 28.21 13.08 46 29248 253773 63205955
Helicobacter infection 27.10 13.08 5 29289 92780 63366948
Injection site mass 27.05 13.08 38 29256 18618 63441110
Extrapyramidal disorder 27.03 13.08 32 29262 13252 63446476
Sporotrichosis 26.82 13.08 6 29288 49 63459679
Anaemia 26.66 13.08 60 29234 293370 63166358
Therapeutic product effect decreased 26.53 13.08 30 29264 193157 63266571
Alcoholism 26.25 13.08 14 29280 1804 63457924
Poisoning 26.23 13.08 32 29262 13668 63446060
Neuroleptic malignant syndrome 26.13 13.08 30 29264 12026 63447702
Product administration interrupted 26.10 13.08 20 29274 4816 63454912
Multiple sclerosis 25.94 13.08 43 29251 24329 63435399
False positive investigation result 25.33 13.08 10 29284 643 63459085
Impaired healing 25.12 13.08 8 29286 102534 63357194
Device expulsion 25.06 13.08 52 29242 34870 63424858
Bipolar disorder 24.73 13.08 24 29270 7936 63451792
Therapy interrupted 24.08 13.08 49 29245 32406 63427322
Foreign body in reproductive tract 23.85 13.08 10 29284 751 63458977
Mydriasis 23.01 13.08 28 29266 11928 63447800
Pancytopenia 22.98 13.08 8 29286 96925 63362803
Sleep apnoea syndrome 22.83 13.08 45 29249 29088 63430640
Plasma cell mastitis 22.55 13.08 5 29289 39 63459689
Device breakage 22.16 13.08 27 29267 11515 63448213
Illness 22.13 13.08 61 29233 48998 63410730
Memory impairment 22.07 13.08 101 29193 104157 63355571
Blister 21.52 13.08 17 29277 129797 63329931
Panic disorder 21.44 13.08 14 29280 2619 63457109
Hypersensitivity 21.16 13.08 67 29227 292618 63167110
Maternal exposure during pregnancy 20.80 13.08 44 29250 220018 63239710
Myofascial pain syndrome 20.54 13.08 13 29281 2305 63457423
Diabetic neuropathy 20.53 13.08 16 29278 3948 63455780
C-reactive protein increased 20.50 13.08 9 29285 94698 63365030
Irritability 20.22 13.08 45 29249 31649 63428079
Depressed mood 20.18 13.08 52 29242 40139 63419589
Hospitalisation 19.96 13.08 85 29209 84996 63374732
Tardive dyskinesia 19.86 13.08 22 29272 8480 63451248
Abnormal uterine bleeding 19.81 13.08 11 29283 1535 63458193
Parkinsonism 19.37 13.08 24 29270 10415 63449313
Generalised anxiety disorder 19.31 13.08 12 29282 2062 63457666
Interstitial lung disease 18.82 13.08 3 29291 61905 63397823
Dental restoration failure 18.31 13.08 9 29285 978 63458750
Respiratory arrest 18.24 13.08 44 29250 32601 63427127
Autonomic nervous system imbalance 18.23 13.08 13 29281 2805 63456923
Delusion 18.20 13.08 25 29269 11992 63447736
Affective disorder 18.11 13.08 18 29276 6128 63453600
Exposure via ingestion 17.86 13.08 13 29281 2896 63456832
Bruxism 17.77 13.08 14 29280 3511 63456217
Somnambulism 17.76 13.08 17 29277 5526 63454202
Syndactyly 17.58 13.08 7 29287 460 63459268
Blood bicarbonate abnormal 17.44 13.08 4 29290 37 63459691
Cerebellar infarction 17.09 13.08 11 29283 2008 63457720
Intentional self-injury 16.98 13.08 37 29257 25650 63434078
Hallucination, auditory 16.95 13.08 25 29269 12799 63446929
Stress cardiomyopathy 16.38 13.08 21 29273 9429 63450299
Fall 16.38 13.08 263 29031 392071 63067657
Rhabdomyolysis 16.33 13.08 51 29243 43900 63415828
Inflammation 16.02 13.08 9 29285 82264 63377464
Headache 15.86 13.08 393 28901 632848 62826880
Major depression 15.79 13.08 19 29275 7999 63451729
Stress 15.67 13.08 67 29227 67100 63392628
Laryngeal granuloma 15.65 13.08 3 29291 10 63459718
Exposure during pregnancy 15.63 13.08 30 29264 155517 63304211
Cleft lip and palate 15.51 13.08 7 29287 628 63459100
Nightmare 15.47 13.08 30 29264 19164 63440564
Mobility decreased 15.37 13.08 20 29274 121139 63338589
Depressed level of consciousness 15.32 13.08 63 29231 62015 63397713
Muscle necrosis 15.17 13.08 7 29287 661 63459067
Dyspareunia 15.14 13.08 11 29283 2444 63457284
Flat affect 15.06 13.08 9 29285 1441 63458287
Hyperhidrosis 14.96 13.08 93 29201 107743 63351985
Therapy cessation 14.87 13.08 39 29255 30418 63429310
Post-traumatic stress disorder 14.77 13.08 15 29279 5236 63454492
Haemoglobin decreased 14.67 13.08 28 29266 145457 63314271
Muscle rigidity 14.60 13.08 22 29272 11478 63448250
Injection site pain 14.45 13.08 106 29188 129694 63330034
Blood pressure orthostatic 14.40 13.08 4 29290 84 63459644
Long QT syndrome 14.37 13.08 12 29282 3267 63456461
Mood altered 14.35 13.08 25 29269 14718 63445010
Thunderclap headache 14.35 13.08 5 29289 226 63459502
Presbyopia 14.13 13.08 6 29288 465 63459263
Renal impairment 14.11 13.08 12 29282 88343 63371385
Anhedonia 13.94 13.08 21 29273 10953 63448775
Akathisia 13.81 13.08 19 29275 9127 63450601
Restless legs syndrome 13.77 13.08 28 29266 18503 63441225
Alcohol withdrawal syndrome 13.75 13.08 7 29287 820 63458908
Embedded device 13.74 13.08 12 29282 3471 63456257
Injection site reaction 13.36 13.08 58 29236 58466 63401262
Complication of device removal 13.23 13.08 14 29280 5128 63454600
Social avoidant behaviour 13.23 13.08 11 29283 2977 63456751
Anticholinergic syndrome 13.18 13.08 10 29284 2372 63457356
Bradykinesia 13.12 13.08 14 29280 5174 63454554

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 152.17 16.35 162 9743 98006 34849020
Sedation 126.33 16.35 77 9828 20929 34926097
Serotonin syndrome 104.56 16.35 67 9838 19866 34927160
Suicidal ideation 89.21 16.35 81 9824 40307 34906719
Anxiety 85.43 16.35 122 9783 99306 34847720
Tardive dyskinesia 76.89 16.35 36 9869 5754 34941272
Irritability 65.52 16.35 55 9850 24635 34922391
Agitation 62.32 16.35 79 9826 57320 34889706
Depression 43.19 16.35 89 9816 97009 34850017
Neuroleptic malignant syndrome 41.59 16.35 37 9868 17897 34929129
Wrong patient 38.95 16.35 9 9896 146 34946880
Tremor 37.07 16.35 76 9829 82511 34864515
Aggression 36.64 16.35 50 9855 38914 34908112
Withdrawal syndrome 35.64 16.35 29 9876 12426 34934600
Electrocardiogram QRS complex prolonged 34.78 16.35 20 9885 4874 34942152
Muscle necrosis 30.84 16.35 11 9894 875 34946151
Obesity 30.71 16.35 27 9878 12851 34934175
Toxicity to various agents 29.88 16.35 124 9781 200238 34746788
Product dose omission issue 28.07 16.35 86 9819 119625 34827401
Insomnia 27.56 16.35 78 9827 103829 34843197
Seizure 27.11 16.35 78 9827 104779 34842247
Drug abuse 25.90 16.35 74 9831 99022 34848004
Orthostatic tremor 25.01 16.35 4 9901 6 34947020
Nightmare 24.43 16.35 25 9880 14366 34932660
General physical health deterioration 23.57 16.35 4 9901 128265 34818761
Pneumonia 23.36 16.35 42 9863 362585 34584441
Hypoparathyroidism 22.92 16.35 8 9897 597 34946429
Anger 22.68 16.35 22 9883 11862 34935164
Orthostatic hypotension 22.47 16.35 32 9873 25887 34921139
Therapy interrupted 21.83 16.35 23 9882 13674 34933352
Feeling abnormal 21.38 16.35 52 9853 63183 34883843
Drug withdrawal syndrome 21.02 16.35 27 9878 19807 34927219
Lens dislocation 20.33 16.35 5 9900 107 34946919
Electrocardiogram QT prolonged 19.92 16.35 39 9866 40913 34906113
Febrile neutropenia 19.84 16.35 7 9898 136842 34810184
Thrombocytopenia 19.45 16.35 10 9895 156237 34790789
Alcoholism 18.14 16.35 11 9894 2954 34944072
Microvascular coronary artery disease 18.14 16.35 4 9901 52 34946974
Akathisia 17.36 16.35 16 9889 8093 34938933
Acute kidney injury 17.32 16.35 38 9867 304950 34642076
Panic attack 17.14 16.35 17 9888 9415 34937611
Post-traumatic stress disorder 16.98 16.35 9 9896 1872 34945154
Hypertensive urgency 16.85 16.35 5 9900 221 34946805
Pre-existing condition improved 16.85 16.35 10 9895 2582 34944444

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 687.67 12.55 643 30117 245124 79468504
Serotonin syndrome 309.10 12.55 201 30559 44826 79668802
Suicidal ideation 137.16 12.55 158 30602 76182 79637446
Anxiety 128.62 12.55 291 30469 248221 79465407
Toxicity to various agents 127.24 12.55 404 30356 421136 79292492
Depression 111.18 12.55 253 30507 216537 79497091
Withdrawal syndrome 85.89 12.55 76 30684 26778 79686850
Agitation 83.42 12.55 143 30617 99572 79614056
Product dose omission issue 67.98 12.55 230 30530 247307 79466321
Tremor 65.48 12.55 178 30582 169905 79543723
Neuroleptic malignant syndrome 65.19 12.55 66 30694 27493 79686135
Irritability 57.40 12.55 75 30685 41069 79672559
Insomnia 55.56 12.55 214 30546 244956 79468672
General physical health deterioration 54.60 12.55 19 30741 275219 79438409
Tardive dyskinesia 53.16 12.55 39 30721 10532 79703096
Febrile neutropenia 51.18 12.55 13 30747 230986 79482642
Sedation 50.91 12.55 80 30680 51815 79661813
Thrombocytopenia 49.78 12.55 20 30740 265239 79448389
Overdose 49.51 12.55 170 30590 184036 79529592
Suspected suicide 48.68 12.55 37 30723 10539 79703089
Dermatitis atopic 48.10 12.55 36 30724 10020 79703608
Panic attack 46.65 12.55 52 30708 24164 79689464
Drug abuse 45.35 12.55 152 30608 162539 79551089
Muscle necrosis 44.95 12.55 18 30742 1440 79712188
Intentional overdose 44.93 12.55 115 30645 105845 79607783
Pancytopenia 43.79 12.55 6 30754 165739 79547889
Drug withdrawal syndrome 40.44 12.55 58 30702 34660 79678968
Neutropenia 39.29 12.55 32 30728 287678 79425950
Anaemia 39.04 12.55 70 30690 444945 79268683
Stiff person syndrome 38.45 12.55 11 30749 311 79713317
Injection site mass 38.29 12.55 43 30717 20141 79693487
Anger 36.80 12.55 39 30721 17123 79696505
Alcoholism 36.78 12.55 21 30739 3702 79709926
Contraindicated product administered 36.59 12.55 8 30752 157530 79556098
Drug intolerance 36.53 12.55 29 30731 264090 79449538
Mydriasis 35.91 12.55 39 30721 17604 79696024
Akathisia 35.53 12.55 34 30726 13225 79700403
Cardio-respiratory arrest 35.36 12.55 107 30653 108403 79605225
Drug screen false positive 35.27 12.55 14 30746 1095 79712533
Renal impairment 34.70 12.55 9 30751 157774 79555854
Anoxia 32.88 12.55 10 30750 351 79713277
Migraine 32.08 12.55 90 30670 87403 79626225
Feeling abnormal 32.05 12.55 134 30626 159065 79554563
Nightmare 31.29 12.55 44 30716 25817 79687811
Total cholesterol/HDL ratio abnormal 30.58 12.55 7 30753 78 79713550
Synovitis 30.58 12.55 10 30750 150724 79562904
Emotional disorder 29.63 12.55 32 30728 14355 79699273
Lower respiratory tract infection 29.13 12.55 7 30753 129213 79584415
Behaviour disorder 28.86 12.55 22 30738 6291 79707337
Depressed mood 28.68 12.55 60 30700 48420 79665208
Treatment failure 28.63 12.55 15 30745 170471 79543157
Somnolence 28.20 12.55 173 30587 238808 79474820
Delusion 28.13 12.55 37 30723 20386 79693242
Electrocardiogram QRS complex prolonged 27.57 12.55 27 30733 10806 79702822
Suicide attempt 27.22 12.55 82 30678 82850 79630778
Device expulsion 26.94 12.55 41 30719 25820 79687808
Hand deformity 26.89 12.55 4 30756 103915 79609713
Foreign body in reproductive tract 26.80 12.55 10 30750 661 79712967
Wound 26.77 12.55 6 30754 116173 79597455
Glossodynia 26.69 12.55 4 30756 103333 79610295
Mental status changes 26.66 12.55 71 30689 66888 79646740
Therapy interrupted 26.25 12.55 45 30715 31296 79682332
Hyperkalaemia 26.18 12.55 6 30754 114392 79599236
Respiratory arrest 25.99 12.55 64 30696 57486 79656142
Parkinsonism 25.93 12.55 32 30728 16552 79697076
Injection site reaction 25.89 12.55 62 30698 54723 79658905
Mental disorder 24.99 12.55 44 30716 31258 79682370
Device breakage 24.21 12.55 25 30735 10650 79702978
Infusion related reaction 24.20 12.55 32 30728 230205 79483423
C-reactive protein increased 23.75 12.55 10 30750 129017 79584611
Surgery 23.54 12.55 44 30716 32722 79680906
Generalised anxiety disorder 23.35 12.55 13 30747 2184 79711444
Attention deficit hyperactivity disorder 23.24 12.55 15 30745 3294 79710334
Pre-existing condition improved 22.43 12.55 18 30742 5545 79708083
Extrapyramidal disorder 22.29 12.55 35 30725 22644 79690984
Hypothermia 22.21 12.55 35 30725 22711 79690917
False positive investigation result 21.92 12.55 10 30750 1102 79712526
Interstitial lung disease 21.92 12.55 8 30752 112592 79601036
Seizure 21.82 12.55 136 30624 188698 79524930
Memory impairment 21.67 12.55 93 30667 111641 79601987
Intentional self-injury 21.40 12.55 42 30718 32377 79681251
Injection site pain 21.40 12.55 103 30657 129735 79583893
Disturbance in attention 21.38 12.55 55 30705 50746 79662882
Joint swelling 21.37 12.55 50 30710 288596 79425032
Fall 20.85 12.55 283 30477 487346 79226282
Poisoning 20.79 12.55 36 30724 25236 79688392
Injection site induration 20.50 12.55 22 30738 9797 79703831
Wrong patient 20.43 12.55 7 30753 361 79713267
Pyrexia 20.32 12.55 166 30594 678543 79035085
Arthropathy 20.31 12.55 23 30737 177088 79536540
Headache 19.80 12.55 358 30402 653414 79060214
Anticholinergic syndrome 19.70 12.55 14 30746 3597 79710031
Orthostatic tremor 19.53 12.55 4 30756 25 79713603
Mucosal inflammation 19.34 12.55 3 30757 75577 79638051
Psoriasis 19.28 12.55 77 30683 89510 79624118
Vision blurred 18.91 12.55 86 30674 105812 79607816
Myofascial pain syndrome 18.82 12.55 11 30749 2026 79711602
Flat affect 18.80 12.55 11 30749 2030 79711598
Muscle twitching 18.73 12.55 34 30726 24730 79688898
Plasma cell mastitis 18.56 12.55 4 30756 33 79713595
Haemoglobin decreased 18.50 12.55 36 30724 222083 79491545
Hepatic function abnormal 18.49 12.55 3 30757 73104 79640524
Stress cardiomyopathy 18.19 12.55 22 30738 11144 79702484
Weight increased 18.17 12.55 175 30585 277211 79436417
Swelling 18.16 12.55 35 30725 216676 79496952
Pleural effusion 17.62 12.55 18 30742 145244 79568384
Hypertensive urgency 17.59 12.55 7 30753 551 79713077
Hepatic enzyme increased 17.58 12.55 27 30733 182583 79531045
Accidental exposure to product by child 17.50 12.55 12 30748 2914 79710714
Malignant neoplasm progression 17.48 12.55 16 30744 135974 79577654
Impaired healing 17.45 12.55 6 30754 87649 79625979
Panic disorder 17.26 12.55 12 30748 2980 79710648
Therapeutic response unexpected 17.18 12.55 29 30731 19917 79693711
Presbyopia 17.12 12.55 7 30753 591 79713037
Hallucination 17.11 12.55 72 30688 85673 79627955
Lens dislocation 17.04 12.55 5 30755 155 79713473
Laryngeal granuloma 16.97 12.55 3 30757 7 79713621
Ideas of reference 16.74 12.55 5 30755 165 79713463
Complication of device removal 16.58 12.55 13 30747 3876 79709752
Aggression 16.35 12.55 50 30710 50908 79662720
Therapy cessation 16.15 12.55 41 30719 37521 79676107
Embedded device 16.14 12.55 12 30748 3307 79710321
Blood bilirubin increased 16.13 12.55 3 30757 66229 79647399
Drug-induced liver injury 16.09 12.55 3 30757 66114 79647514
Tachyphrenia 16.03 12.55 10 30750 2070 79711558
Muscle rigidity 15.94 12.55 28 30732 19854 79693774
Hypoparathyroidism 15.93 12.55 8 30752 1090 79712538
Antisocial behaviour 15.86 12.55 7 30753 714 79712914
Bipolar disorder 15.62 12.55 17 30743 7690 79705938
Euphoric mood 15.58 12.55 17 30743 7709 79705919
Feeling of despair 15.54 12.55 11 30749 2810 79710818
Rheumatoid arthritis 15.51 12.55 36 30724 208434 79505194
Ascites 15.34 12.55 5 30755 75557 79638071
Exposure via ingestion 15.27 12.55 14 30746 5160 79708468
Device dislocation 15.19 12.55 32 30728 25938 79687690
Rhabdomyolysis 15.01 12.55 79 30681 103052 79610576
Dizziness 14.78 12.55 285 30475 526156 79187472
Systemic lupus erythematosus 14.70 12.55 15 30745 121134 79592494
Product administered at inappropriate site 14.25 12.55 12 30748 3953 79709675
Platelet count decreased 14.18 12.55 34 30726 194630 79518998
Therapeutic product effect decreased 14.13 12.55 26 30734 163837 79549791
Gynaecomastia 13.95 12.55 16 30744 7665 79705963
Dental restoration failure 13.78 12.55 7 30753 977 79712651
Disease progression 13.59 12.55 32 30728 184330 79529298
Helicobacter infection 13.48 12.55 5 30755 69699 79643929
Depressed level of consciousness 13.36 12.55 73 30687 96579 79617049
Hallucination, visual 13.32 12.55 35 30725 32694 79680934
Hyperhidrosis 13.29 12.55 102 30658 151390 79562238
Abnormal uterine bleeding 13.21 12.55 7 30753 1066 79712562
Blister 13.17 12.55 16 30744 119460 79594168
Tension 13.16 12.55 12 30748 4392 79709236
Pupillary deformity 13.14 12.55 3 30757 33 79713595
Blood bicarbonate abnormal 13.11 12.55 4 30756 142 79713486
Diabetic neuropathy 13.10 12.55 14 30746 6202 79707426
Cerebellar infarction 13.03 12.55 11 30749 3636 79709992
Injection site abscess 12.93 12.55 8 30752 1632 79711996
Aspartate aminotransferase increased 12.87 12.55 21 30739 138620 79575008
Complication of device insertion 12.86 12.55 14 30746 6336 79707292
Psychotic disorder 12.71 12.55 40 30720 41362 79672266
Hallucination, auditory 12.69 12.55 26 30734 20667 79692961
Hypersensitivity 12.68 12.55 55 30705 262184 79451444

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05BE01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Azaspirodecanedione derivatives
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:35941 serotonin agonists
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D014149 Tranquilizing Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Generalized anxiety disorder indication 21897009 DOID:14320
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.51 Basic
pKa2 2.23 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1A GPCR PARTIAL AGONIST EC50 7.25 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR Ki 7.68 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.32 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.40 CHEMBL
Cytochrome P450 3A4 Enzyme Ki 5.13 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 6.60 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 6.41 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 6.04 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 6.08 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 6.44 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 6.18 CHEMBL
D(4) dopamine receptor GPCR Ki 7 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 6.28 DRUG MATRIX
Solute carrier family 22 member 2 Transporter IC50 4.92 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.77 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 4.34 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.77 CHEMBL
Membrane-associated progesterone receptor component 1 Membrane receptor IC50 5.47 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 6.92 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 8.42 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.32 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.32 CHEMBL
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 6.40 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.40 IUPHAR
D(1A) dopamine receptor GPCR Ki 5.21 CHEMBL
D(2) dopamine receptor GPCR Ki 7.36 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 6 CHEMBL
Alpha-2A adrenergic receptor GPCR IC50 5 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.75 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR IC50 7.02 CHEMBL
Adrenergic receptor alpha-2 GPCR IC50 5 CHEMBL
Dopamine receptor GPCR IC50 6.92 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 6.86 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 4.80 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 6.76 CHEMBL

External reference:

IDSource
4019646 VUID
N0000147739 NUI
D00702 KEGG_DRUG
33386-08-2 SECONDARY_CAS_RN
1827 RXNORM
C0006462 UMLSCUI
CHEBI:3223 CHEBI
CHEMBL49 ChEMBL_ID
DB00490 DRUGBANK_ID
CHEMBL1200399 ChEMBL_ID
D002065 MESH_DESCRIPTOR_UI
2477 PUBCHEM_CID
36 IUPHAR_LIGAND_ID
3456 INN_ID
TK65WKS8HL UNII
37673 MMSL
4308 MMSL
d00182 MMSL
387523009 SNOMEDCT_US
419484002 SNOMEDCT_US
91452003 SNOMEDCT_US
4018813 VANDF
4019646 VANDF
001468 NDDF
004586 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0053 TABLET 5 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0053 TABLET 5 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0054 TABLET 10 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0054 TABLET 10 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1003 TABLET 15 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1003 TABLET 15 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5200 TABLET 30 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5200 TABLET 30 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1140 TABLET 5 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1140 TABLET 5 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1145 TABLET 7.50 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1145 TABLET 7.50 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1150 TABLET 10 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1150 TABLET 10 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1165 TABLET 15 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1165 TABLET 15 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1175 TABLET 30 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1175 TABLET 30 mg ORAL ANDA 27 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-4575 TABLET 10 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-4595 TABLET 5 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-4596 TABLET 15 mg ORAL ANDA 29 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7633 TABLET 5 mg ORAL ANDA 30 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7634 TABLET 10 mg ORAL ANDA 30 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7635 TABLET 15 mg ORAL ANDA 30 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7689 TABLET 15 mg ORAL ANDA 30 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7689 TABLET 15 mg ORAL ANDA 30 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7714 TABLET 5 mg ORAL ANDA 30 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7714 TABLET 5 mg ORAL ANDA 30 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7718 TABLET 10 mg ORAL ANDA 30 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7718 TABLET 10 mg ORAL ANDA 30 sections